期刊文献+

血管内超声在评估肺动脉高压中的应用 被引量:1

Assessment of Pulmonary Arterial Hypertension by Intravascular Ultrasound
下载PDF
导出
摘要 肺动脉高压是由肺小动脉结构重建引起肺动脉压和肺血管阻力进行性增加,最终导致右心增大、右室壁肥厚、右心功能衰竭而死亡的疾病,是一组临床常见症候群。目前对肺动脉高压病情的主要评估方法是组织学活检,但由于肺动脉高压肺血管病变具有不均一性,且活检需要手术切开,所以使得肺组织活检在临床评价肺动脉高压病变方面受到限制。近年来有研究报道血管内超声可以评价肺动脉高压患者的肺血管损害程度。现就血管内超声在评估肺动脉高压的研究及发展趋势作一综述。 Pulmonary arterial hypertension ( PAH ) is a common clinical syndrome characterized by the remodeling of the small pulmonary arteries that results in a rise in the pulmonary arterial pressure and pulmonary vascular resistance. This eventually leads to right heart enlargement, right ventricular hypertrophy, right heart failure, and death. Currently, the main assessment of PAH is a histological biopsy, but its use has been limited because of the heterogeneity of pulmonary artery changes in PAH and the demand for the use of thoracotomy. In recent years, several studies on the use of intravascular ultrasound ( IVUS ) in evaluating the severity of pulmonary vascular damage in patients with PAH make it clear that IVUS could be effective in the assessment of PAH. This article reviews the assessment of pulmonary arterial hypertension by IVUS, and its development.
出处 《心血管病学进展》 CAS 2012年第5期609-612,共4页 Advances in Cardiovascular Diseases
关键词 肺动脉高压 血管内超声 评估 pulmonary arterial hypertension intravascular ultrasound assessment
  • 相关文献

参考文献2

二级参考文献48

  • 1Takagi A,Tsurumi Y,Ishii Y,et al.Clinical potential of intravascular ultrasound for physiolopcal assessment of coronary stenosis:relationship between quantitative ultrasound tomography and pressure-derived fractional flow reserve.Circulation,1999,100:250-255.
  • 2Jasti V,Ivan E,Yalamanchili V,et al.Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis.Circulation,2004,110:2831-2836.
  • 3Lee CH,Tai BC,Soon CY,et al.New set of intravascular ultrasound-derived anatomic criteria for defining functionally significant stenoses in small coronary artenes(results from Intravascular Ultrasound Diagnostic Evaluation of Atherosclerosis in Singapore[IDEAS] study).Am J Cardiol,2010,105:1378-1384.
  • 4Colombo A,Hall P,Nakamura S,et al.Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.Circulation,1995,91:1676-1688.
  • 5Sonoda S,Morino Y,Ako J,et al.Impact of final stent dimensions on long-term results foUowing sirolimus-eluting stent implantation:serial intravascular ultrasound analysis from the SIRIUS trial.J Am Coll Cardiol,2004,43:1959-1963.
  • 6Hong MK,Mintz GS,Lee CW,et al.Intravascular ultrasound predictors of anpographic restenosis after sirolimus-eluting stent implantation.Eur Heart J,2006,27:1305-1310.
  • 7Hoye A,Iakovou L,Ge L,et al.Long-term outcomes after stenting of bifurcation lesions with the " crush" technique:predictors of an adverse outcome.J Am Coll Cardiol,2006,47:1949-1 958.
  • 8Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.N Engl J Med,2003,349:1315-1323.
  • 9Weissman NJ,Koglin J,Cox DA,et al.Polymer-based paclitaxel-eluting stents reduce instent neointimal tissue proliferation:a serial volumetric intravascular ultrasound analysis from the TAXUS-Ⅳ trial.J Am Coll Cardiol,2005,45:1201 -1205.
  • 10Hong MK,Mintz GS,Lee CW,et al.Late stent malapposition after drugeluting stent implantation.An intravascular ultrasound analysis with long-term follow-up.Circulation,2006,113:414-419.

共引文献8

同被引文献21

  • 1Gall, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension :the Task Force for the Diagnosis and Treatment of Puhnonary Hyperlension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) , endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [ J ]. Eur Heart J, 2009, 30(20) :2493-2537.
  • 2Benza RL, Miller DP, Barst P,J, et al. An evaluation of hmg-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry[ J]. Chest, 2012, 142 (2) :448-456.
  • 3Makeljee D, St George D, Coieiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonax, arterial hypertension:application of a registry approach [ J ]. Ann Rheum Dis, 2003, 62(11) :1088-1093.
  • 4Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated puhnonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenntype [J]. Chest, 2010, 138(6) :1383-1394.
  • 5Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vaseulopathies in pulmonary hyperlension[J]. J Am Coil Cmdiol, 2004, 43( 12 Suppl S) :25S-32S.
  • 6Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension [ J ]. J Am Coil Cardiol, 2009, 54( 1 Suppl) :S3-S9.
  • 7Hoeper MM, Bogaard HJ, Condlift) R, et al. Definitions and diagnosis of pulmonary hypertension [ J ]. J Am Coll Cardiol, 2013, 62(25 Suppl):D42-D50.
  • 8Bressollette E, Dupuis J, Bonan R, et al. Intravascular ultrasound assessment ot puhnona vascular disease in patients with pulmonary hypertension [J].Chest, 2001, 120 ( 3 ) : 809- 815.
  • 9O'Rourke MF, Staessen JA, Vlachopoulos C, et al. Clinical applications of arterial stiffness ; definitions and reference values [ J ]. Am J Hypertens, 2002, 15 (5) :426-444.
  • 10Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension[ J]. Am J Respir Crit Care Med, 2012, 186(3) :261-272.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部